- Home
- LECO vs EXAS Comparison
LECO vs EXAS Comparison
Compare LECO & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LECO | EXAS |
|---|---|---|
| Founded | 1895 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 11.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LECO | EXAS |
|---|---|---|
| Price | $243.21 | $101.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $244.00 | $77.94 |
| AVG Volume (30 Days) | 356.4K | ★ 10.8M |
| Earning Date | 10-30-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 11.30 | N/A |
| EPS | ★ 9.34 | N/A |
| Revenue | ★ $4,176,319,000.00 | $3,082,033,000.00 |
| Revenue This Year | $7.92 | $19.40 |
| Revenue Next Year | $6.01 | $13.51 |
| P/E Ratio | $26.11 | ★ N/A |
| Revenue Growth | 3.24 | ★ 14.47 |
| 52 Week Low | $161.11 | $38.81 |
| 52 Week High | $251.55 | $101.95 |
Technical Indicators
Market Signals| Indicator | LECO | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 55.96 | 89.65 |
| Support Level | $237.95 | $100.95 |
| Resistance Level | $247.42 | $101.95 |
| Average True Range (ATR) | 5.91 | 0.35 |
| MACD | 1.23 | -0.87 |
| Stochastic Oscillator | 63.91 | 61.17 |
Price Performance
Historical ComparisonAbout LECO Lincoln Electric Holdings Inc.
Lincoln Electric is a leading manufacturer of welding, cutting, and brazing products. Its portfolio includes arc-welding solutions, plasma and oxy-fuel cutting systems, brazing and soldering alloys, and automation solutions. Lincoln Electric serves clients across general fabrication, heavy industries, automotive, construction, shipbuilding, energy, and process industries, among others. Based in Cleveland, Lincoln Electric operates in 19 countries and employs 11,000 worldwide. The company generated roughly $4 billion in sales in 2024.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.